UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
Together, they create a comprehensive support system for your body during Lyme treatment
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring peptide in the human body that binds copper ions, an essential element for tissue repair and cellular function
Dataset of proteins identified and quantified in CSF samples from ALS patients and healthy controls 40035_2025_496_MOESM3_ESM.xlsx (download XLSX Additional file 3: Table S4
Redefining Whats Possible Ive shared these insights globallyfrom the Undersea and Hyperbaric Medical Society (UHMS) to the Yale New Haven Health and Bridgeport Hospital Wound Science Symposium
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, is a naturally occurring copper peptide studied for collagen-related pathways, tissue remodeling, antioxidant defense, and skin repair [7] [8]